YPSOMED

Ypsomed is the leading developer and manufacturer of self-injection systems for liquid medications, offering the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices. Backed by a proven track record of over 40 years, Ypsomed's tailored solutions are delivered with best-in-class execution and ready to integrate with digital health services. Our portfolio, including flagship products YpsoMate and UnoPen, provides a proven foundation that accelerates development, reduces project risk, and scales from early clinical trials through to commercial launch. Engineered to support a wide range of drug formulations, viscosities, and fill volumes, they enable customization without changing core device design. Over four decades, Ypsomed has built a network of strategic partners across primary containers, fill-finish, and final assembly. These partnerships help pharmaceutical companies reduce development costs and timelines while ensuring reliable, high-quality combination products. Manufacturing excellence is the foundation of our offering. Ypsomed manages critical manufacturing processes in-house, from tool design and injection molding to automated assembly. Co-located expertise in Burgdorf, Switzerland, enables efficient collaboration, high product quality, and control over timelines and standards. This is complimented by a comprehensive range of services and support across the full product lifecycle. Sustainability is integrated into our corporate strategy through our NetZero Program, ecodesign principles, and responsible manufacturing practices. Our next-generation platforms reflect this commitment, including the award-winning YpsoLoop autoinjector, designed for automated disassembly and efficient material recovery. Ypsomed is headquartered in Burgdorf, Switzerland, employing more than 2,000 people worldwide, all committed to making selfcare simpler and easier.